The role of gender and organ specific autoimmunity

Autoimmunity Reviews

Volumn 11, Issue 6-7, 2012, Pages

  Nussinovitch, Udi ^a   Shoenfeld, Yehuda ^b,c  

^a MEDICAL CORPS   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Crohn's disease; Multiple sclerosis; Myocarditis; Sex hormones; Ulcerative colitis

Indexed keywords

COLECALCIFEROL; CYTOKINE; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; ORAL CONTRACEPTIVE AGENT; PRASTERONE; PROGESTERONE; RECOMBINANT INTERLEUKIN 10; SEX HORMONE; TESTOSTERONE;

AGE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CARDIOVASCULAR RISK; CELIAC DISEASE; CENTRAL NERVOUS SYSTEM; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG MEGADOSE; ESTROGEN THERAPY; GENDER; GUILLAIN BARRE SYNDROME; HEART FAILURE; HUMAN; IMMUNOMODULATION; INCIDENCE; LONG TERM CARE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYOCARDITIS; NEUROPROTECTION; NONHUMAN; PERIPHERAL VASCULAR DISEASE; REVIEW; RHEUMATIC FEVER; RISK FACTOR; SEX DIFFERENCE; STROKE; ULCERATIVE COLITIS;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM DISEASES; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, X; FEMALE; GASTROINTESTINAL DISEASES; GONADAL STEROID HORMONES; HUMANS; MALE; SEX FACTORS;

EID: 84858450790     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.11.001     Document Type: Review

References (108)

1. Shoenfeld Y., Isenberg D.A. The mosaic of autoimmunity. Immunol Today 1989, 10:123-126.
2. Sadovnick A.D. Genetic background of multiple sclerosis. Autoimmun Rev 2011.
3. McCarthy M. The "gender gap" in autoimmune disease. Lancet 2000, 356:1088.
4. Ortona E., Margutti P., Matarrese P., Franconi F., Malorni W. Redox state, cell death and autoimmune diseases: a gender perspective. Autoimmun Rev 2008, 7:579-584.
5. Invernizzi P., Pasini S., Selmi C., Gershwin M.E., Podda M. Female predominance and X chromosome defects in autoimmune diseases. J Autoimmun 2009, 33:12-16.
6. McCombe P.A., Greer J.M., Mackay I.R. Sexual dimorphism in autoimmune disease. Curr Mol Med 2009, 9:1058-1079.
7. Ahmed S.A., Hissong B.D., Verthelyi D., Donner K., Becker K., Karpuzoglu-Sahin E. Gender and risk of autoimmune diseases: possible role of estrogenic compounds. Environ Health Perspect 1999, 107(Suppl 5):681-686.
8. Lleo A., Battezzati P.M., Selmi C., Gershwin M.E., Podda M. Is autoimmunity a matter of sex?. Autoimmun Rev 2008, 7:626-630.
9. Di Comite G., Grazia Sabbadini M., Corti A., Rovere-Querini P., Manfredi A.A. Conversation galante: how the immune and the neuroendocrine systems talk to each other. Autoimmun Rev 2007, 7:23-29.
10. Achiron A., Gurevich M. Gender effects in relapsing-remitting multiple sclerosis: correlation between clinical variables and gene expression molecular pathways. J Neurol Sci 2009, 286:47-53.
11. Keefe D.L. Sex hormones and neural mechanisms. Arch Sex Behav 2002, 31:401-403.
12. Rubtsov A.V., Rubtsova K., Kappler J.W., Marrack P. Genetic and hormonal factors in female-biased autoimmunity. Autoimmun Rev 2010, 9:494-498.
13. Zandman-Goddard G., Peeva E., Shoenfeld Y. Gender and autoimmunity. Autoimmun Rev 2007, 6:366-372.
14. Shoenfeld Y., Zandman-Goddard G., Stojanovich L., Cutolo M., Amital H., Levy Y., et al. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases-2008. Isr Med Assoc J 2008, 10:8-12.
15. Gleicher N., Barad D.H. Gender as risk factor for autoimmune diseases. J Autoimmun 2007, 28:1-6.
16. Huber S.A., Kupperman J., Newell M.K. Hormonal regulation of CD4(+) T-cell responses in coxsackievirus B3-induced myocarditis in mice. J Virol 1999, 73:4689-4695.
17. Fairweather D., Cihakova D. Alternatively activated macrophages in infection and autoimmunity. J Autoimmun 2009, 33:222-230.
18. Fairweather D., Rose N.R. Women and autoimmune diseases. Emerg Infect Dis 2004, 10:2005-2011.
19. Holmdahl R. Estrogen exaggerates lupus but suppresses T-cell-dependent autoimmune disease. J Autoimmun 1989, 2:651-656.
20. Duan R.S., Link H., Xiao B.G. Dehydroepiandrosterone therapy ameliorates experimental autoimmune myasthenia gravis in Lewis rats. J Clin Immunol 2003, 23:100-106.
21. Soldan S.S., Alvarez Retuerto A.I., Sicotte N.L., Voskuhl R.R. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J Immunol 2003, 171:6267-6274.
22. Aloisi A.M., Bonifazi M. Sex hormones, central nervous system and pain. Horm Behav 2006, 50:1-7.
23. Hiemke C., Banger M., Kohsik R., Hundt M., Ghraf R. Actions of sex hormones on the brain. Prog Neuropsychopharmacol Biol Psychiatry 1992, 16:377-388.
24. McCombe P.A., Csurhes P.A., Greer J.M. Studies of HLA associations in male and female patients with Guillain-Barre syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). J Neuroimmunol 2006, 180:172-177.
25. Gold S.M., Voskuhl R.R. Estrogen and testosterone therapies in multiple sclerosis. Prog Brain Res 2009, 175:239-251.
26. El-Etr M., Ghoumari A., Sitruk-Ware R., Schumacher M. Hormonal influences in multiple sclerosis: new therapeutic benefits for steroids. Maturitas 2011, 68:47-51.
27. Delpy L., Douin-Echinard V., Garidou L., Bruand C., Saoudi A., Guery J.C. Estrogen enhances susceptibility to experimental autoimmune myasthenia gravis by promoting type 1-polarized immune responses. J Immunol 2005, 175:5050-5057.
28. Meriggioli M.N., Sanders D.B. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009, 8:475-490.
29. Beekman R., Kuks J.B., Oosterhuis H.J. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol 1997, 244:112-118.
30. Poulas K., Tzartos S.J. The gender gap in autoimmune disease. Lancet 2001, 357:234.
31. Kaur M., Schmeier S., MacPherson C.R., Hofmann O., Hide W.A., Taylor S., et al. Prioritizing genes of potential relevance to diseases affected by sex hormones: an example of myasthenia gravis. BMC Genomics 2008, 9:481.
32. Pal Z., Gal A., Remenyi V., Tordai A., Molnar M.J. Oestrogen receptor alpha gene intronic polymorphisms and autoimmune myasthenia gravis in Caucasian women. Neuromuscul Disord 2009, 19:822-824.
33. Leker R.R., Karni A., Brenner T., Weidenfeld J., Abramsky O. Effects of sex hormones on experimental autoimmune myasthenia gravis. Eur J Neurol 2000, 7:203-206.
34. Barzegar M., Dastgiri S., Karegarmaher M.H., Varshochiani A. Epidemiology of childhood Guillan-Barre syndrome in the north west of Iran. BMC Neurol 2007, 7:22.
35. Hauck L.J., White C., Feasby T.E., Zochodne D.W., Svenson L.W., Hill M.D. Incidence of Guillain-Barre syndrome in Alberta, Canada: an administrative data study. J Neurol Neurosurg Psychiatry 2008, 79:318-320.
36. The prognosis and main prognostic indicators of Guillain-Barre syndrome. A multicentre prospective study of 297 patients. The Italian Guillain-Barre Study Group. Brain 1996, 119(Pt 6):2053-2061.
37. Cuadrado J.I., de Pedro-Cuesta J., Ara J.R., Cemillan C.A., Diaz M., Duarte J., et al. Public health surveillance and incidence of adulthood Guillain-Barre syndrome in Spain, 1998-1999: the view from a sentinel network of neurologists. Neurol Sci 2004, 25:57-65.
38. Nelson L., Gormley R., Riddle M.S., Tribble D.R., Porter C.K. The epidemiology of Guillain-Barre Syndrome in U.S. military personnel: a case-control study. BMC Res Notes 2009, 2:171.
39. Flachenecker P. Epidemiology of neuroimmunological diseases. J Neurol 2006, 253(Suppl 5):V2-V8.
40. Dhar R., Stitt L., Hahn A.F. The morbidity and outcome of patients with Guillain-Barre syndrome admitted to the intensive care unit. J Neurol Sci 2008, 264:121-128.
41. Azuma T., Matsubara T., Shima Y., Haeno S., Fujimoto T., Tone K., et al. Neurosteroids in cerebrospinal fluid in neurologic disorders. J Neurol Sci 1993, 120:87-92.
42. Geleijns K., Schreuder G.M., Jacobs B.C., Sintnicolaas K., van Koningsveld R., Meulstee J., et al. HLA class II alleles are not a general susceptibility factor in Guillain-Barre syndrome. Neurology 2005, 64:44-49.
43. Jacobson D.L., Gange S.J., Rose N.R., Graham N.M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997, 84:223-243.
44. Knudsen G.P. Gender bias in autoimmune diseases: X chromosome inactivation in women with multiple sclerosis. J Neurol Sci 2009, 286:43-46.
45. Celius E.G., Harbo H.F., Egeland T., Vartdal F., Vandvik B., Spurkiand A. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci 2000, 178:132-135.
46. Sellner J., Kraus J., Awad A., Milo R., Hemmer B., Stuve O. The increasing incidence and prevalence of female multiple sclerosis-a critical analysis of potential environmental factors. Autoimmun Rev 2011, 10:495-502.
47. Bergamaschi R. Prognostic factors in multiple sclerosis. Int Rev Neurobiol 2007, 79:423-447.
48. Alonso A., Clark C.J. Oral contraceptives and the risk of multiple sclerosis: a review of the epidemiologic evidence. J Neurol Sci 2009, 286:73-75.
49. Gold S.M., Chalifoux S., Giesser B.S., Voskuhl R.R. Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone. J Neuroinflammation 2008, 5:32.
50. Sicotte N.L., Giesser B.S., Tandon V., Klutch R., Steiner B., Drain A.E., et al. Testosterone treatment in multiple sclerosis: a pilot study. Arch Neurol 2007, 64:683-688.
51. Cohen J.A. Emerging therapies for relapsing multiple sclerosis. Arch Neurol 2009, 66:821-828.
52. Sicotte N.L., Liva S.M., Klutch R., Pfeiffer P., Bouvier S., Odesa S., et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 2002, 52:421-428.
53. Vukusic S., Ionescu I., El-Etr M., Schumacher M., Baulieu E.E., Cornu C., et al. The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART'MUS) trial: rationale, objectives and state of advancement. J Neurol Sci 2009, 286:114-118.
54. Correale J., Ysrraelit M.C., Gaitan M.I. Gender differences in 1,25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects. J Immunol 2010, 185:4948-4958.
55. Brant S.R., Nguyen G.C. Is there a gender difference in the prevalence of Crohn's disease or ulcerative colitis?. Inflamm Bowel Dis 2008, 14(Suppl 2):S2-S3.
56. Kane S. Gender issues in inflammatory bowel disease. Womens Health (Lond Engl) 2005, 1:401-407.
57. Gupta N., Bostrom A.G., Kirschner B.S., Ferry G.D., Winter H.S., Baldassano R.N., et al. Gender differences in presentation and course of disease in pediatric patients with Crohn disease. Pediatrics 2007, 120:e1418-e1425.
58. Siegel C.A., Siegel L.S., Hyams J.S., Kugathasan S., Markowitz J., Rosh J.R., et al. Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis 2011, 17:30-38.
59. Browning B.L., Annese V., Barclay M.L., Bingham S.A., Brand S., Buning C., et al. Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 Caucasian cohorts. J Med Genet 2008, 45:36-42.
60. Garcia Rodriguez L.A., Gonzalez-Perez A., Johansson S., Wallander M.A. Risk factors for inflammatory bowel disease in the general population. Aliment Pharmacol Ther 2005, 22:309-315.
61. Zimmer V., Widmann T., Muller M., Ong M.F., Stein J.M., Pfreundschuh M., et al. Genotypic interaction and gender specificity of common genetic variants in the p53/mdm2 network in Crohn's disease. Digestion 2010, 81:246-251.
62. Weigert J., Obermeier F., Neumeier M., Wanninger J., Filarsky M., Bauer S., et al. Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn's disease. Inflamm Bowel Dis 2010, 16:630-637.
63. Hayee B., Rahman F.Z., Tempero J., McCartney S., Bloom S.L., Segal A.W., et al. The neutrophil respiratory burst and bacterial digestion in Crohn's disease. Dig Dis Sci 2011, 56:1482-1488.
64. Ooi C.J., Fock K.M., Makharia G.K., Goh K.L., Ling K.L., Hilmi I., et al. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol 2010, 25:453-468.
65. Bai A., Guo Y., Shen Y., Xie Y., Lu N. Gender-related and city- and countryside-related differences in patients with ulcerative colitis in a Chinese population. Intern Med 2008, 47:2103-2107.
66. Soderlund S., Granath F., Brostrom O., Karlen P., Lofberg R., Ekbom A., et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology 2010, 138:1697-1703.
67. Ullman T.A. Inflammatory bowel disease-associated cancers: does gender change incidence?. Gastroenterology 2010, 138:1658-1660.
68. Tedde A., Laura Putignano A., Bagnoli S., Congregati C., Milla M., Sorbi S., et al. Interleukin-10 promoter polymorphisms influence susceptibility to ulcerative colitis in a gender-specific manner. Scand J Gastroenterol 2008, 43:712-718.
69. Rezaie A., Khalaj S., Shabihkhani M., Nikfar S., Zamani M.J., Mohammadirad A., et al. Study on the correlations among disease activity index and salivary transforming growth factor-beta 1 and nitric oxide in ulcerative colitis patients. Ann N Y Acad Sci 2007, 1095:305-314.
70. Ivarsson A., Persson L.A., Nystrom L., Hernell O. The Swedish coeliac disease epidemic with a prevailing twofold higher risk in girls compared to boys may reflect gender specific risk factors. Eur J Epidemiol 2003, 18:677-684.
71. Tiberti C., Bao F., Bonamico M., Verrienti A., Picarelli A., Di Tola M., et al. Celiac disease-associated transglutaminase autoantibody target domains at diagnosis are age and sex dependent. Clin Immunol 2003, 109:318-324.
72. Bai D., Brar P., Holleran S., Ramakrishnan R., Green P.H. Effect of gender on the manifestations of celiac disease: evidence for greater malabsorption in men. Scand J Gastroenterol 2005, 40:183-187.
73. Llorente-Alonso M.J., Fernandez-Acenero M.J., Sebastian M. Gluten intolerance: sex and age-related features. Can J Gastroenterol 2006, 20:719-722.
74. Bardella M.T., Fredella C., Saladino V., Trovato C., Cesana B.M., Quatrini M., et al. Gluten intolerance: gender- and age-related differences in symptoms. Scand J Gastroenterol 2005, 40:15-19.
75. Ciacci C., Cirillo M., Sollazzo R., Savino G., Sabbatini F., Mazzacca G. Gender and clinical presentation in adult celiac disease. Scand J Gastroenterol 1995, 30:1077-1081.
76. Farthing M.J., Rees L.H., Edwards C.R., Dawson A.M. Male gonadal function in coeliac disease: 2. Sex hormones. Gut 1983, 24:127-135.
77. Agarwal M., Naghi J., Philip K., Phan A., Willix R.D., Schwarz E.R. Growth hormone and testosterone in heart failure therapy. Expert Opin Pharmacother 2010, 11:1835-1844.
78. Nussinovitch U., Shoenfeld Y. Intravenous immunoglobulin - indications and mechanisms in cardiovascular diseases. Autoimmun Rev 2008, 7:445-452.
79. Nussinovitch U., Shoenfeld Y. Autoimmunity and heart diseases: pathogenesis and diagnostic criteria. Arch Immunol Ther Exp (Warsz) 2009, 57:95-104.
80. Huber S.A., Job L.P., Auld K.R. Influence of sex hormones on Coxsackie B-3 virus infection in Balb/c mice. Cell Immunol 1982, 67:173-179.
81. Nussinovitch U., Shoenfeld Y. The clinical and diagnostic significance of anti-myosin autoantibodies in cardiac disease. Clin Rev Allergy Immunol 2011.
82. Cocker M.S., Abdel-Aty H., Strohm O., Friedrich M.G. Age and gender effects on the extent of myocardial involvement in acute myocarditis: a cardiovascular magnetic resonance study. Heart 2009, 95:1925-1930.
83. Nussinovitch U., Shoenfeld Y. Anti-troponin autoantibodies and the cardiovascular system. Heart 2010, 96:1518-1524.
84. Nussinovitch U., Shoenfeld Y. Autoimmune dilated cardiomyopathy. Diagnostic criteria for autoimmune diseases New Jersey 2008, 367-373. The Humana Press Inc, USA. Y. Shoenfeld, R. Cervera, M.E. Gershwin (Eds.).
85. Nussinovitch U., Shoenfeld Y. The diagnostic and clinical significance of anti-muscarinic receptor autoantibodies. Clin Rev Allergy Immunol 2011.
86. Nussinovitch U., Shoenfeld Y. The clinical significance of anti-beta-1 adrenergic receptor autoantibodies in cardiac disease. Clin Rev Allergy Immunol 2010.
87. Nussinovitch U., de Carvalho J.F., Pereira R.M., Shoenfeld Y. Glucocorticoids and the cardiovascular system: state of the art. Curr Pharm Des 2010, 16:3574-3585.
88. Kivity S., Katz U., Daniel N., Nussinovitch U., Papageorgiou N., Shoenfeld Y. Evidence for the use of intravenous immunoglobulins-a review of the literature. Clin Rev Allergy Immunol 2010, 38:201-269.
89. De Maria R., Gavazzi A., Recalcati F., Baroldi G., De Vita C., Camerini F. Comparison of clinical findings in idiopathic dilated cardiomyopathy in women versus men. The Italian Multicenter Cardiomyopathy Study Group (SPIC). Am J Cardiol 1993, 72:580-585.
90. Dini F.L., Dell'Anna R., Micheli A., Michelassi C., Rovai D. Impact of blunted pulmonary venous flow on the outcome of patients with left ventricular systolic dysfunction secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2000, 85:1455-1460.
91. Heidecker B., Lamirault G., Kasper E.K., Wittstein I.S., Champion H.C., Breton E., et al. The gene expression profile of patients with new-onset heart failure reveals important gender-specific differences. Eur Heart J 2010, 31:1188-1196.
92. Aguero J., Navarro J., Medina M.C., Almenar L., Chirivella M., Martinez-Dolz L., et al. Clinical variables associated with the presence of inflammatory infiltrates in patients with dilated cardiomyopathy undergoing heart transplantation. Transplant Proc 2008, 40:3017-3019.
93. Jankowska E.A., Rozentryt P., Ponikowska B., Hartmann O., Kustrzycka-Kratochwil D., Reczuch K., et al. Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA 2009, 301:1892-1901.
94. Guder G., Frantz S., Bauersachs J., Allolio B., Ertl G., Angermann C.E., et al. Low circulating androgens and mortality risk in heart failure. Heart 2010, 96:504-509.
95. Iellamo F., Volterrani M., Caminiti G., Karam R., Massaro R., Fini M., et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 2010, 56:1310-1316.
96. Nussinovitch U. The association between mycoplasma infections and atherosclerosis: myth or clinical reality?. Isr Med Assoc J 2010, 12:439-440.
97. Glezerman M. Discrimination by good intention: gender-based medicine. Isr Med Assoc J 2009, 11:39-41.
98. Lambrinoudaki I., Christodoulakos G., Rizos D., Economou E., Argeitis J., Vlachou S., et al. Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women. Eur J Endocrinol 2006, 154:907-916.
99. Liu P.P., Fukuoka M. Sex hormones as novel risk biomarkers for atherosclerosis in peripheral vascular disease. J Am Coll Cardiol 2007, 50:1077-1079.
100. Sex, hormones, and atherosclerosis. Lancet 1986, 2:552-553.
101. Malkin C.J., Pugh P.J., Jones R.D., Jones T.H., Channer K.S. Testosterone as a protective factor against atherosclerosis-immunomodulation and influence upon plaque development and stability. J Endocrinol 2003, 178:373-380.
102. Griggs R.M., Bluth E.I. Noninvasive risk assessment for stroke: special emphasis on carotid atherosclerosis, sex-related differences, and the development of an effective screening strategy. AJR Am J Roentgenol 2011, 196:259-264.
103. Price J.F., Leng G.C. Steroid sex hormones for lower limb atherosclerosis. Cochrane Database Syst Rev 2000, CD000188.
104. Nussinovitch U., Shoenfeld Y. Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality. Autoimmun Rev 2011, 10:259-266.
105. Tivesten A., Mellstrom D., Jutberger H., Fagerberg B., Lernfelt B., Orwoll E., et al. Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men, the MrOS study in Sweden. J Am Coll Cardiol 2007, 50:1070-1076.
106. Muller M., van den Beld A.W., Bots M.L., Grobbee D.E., Lamberts S.W., van der Schouw Y.T. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 2004, 109:2074-2079.
107. Klosiewicz-Wasek B., Ceremuzynski L., Polonski L., Lukaszewicz R., Wasilewski J. Association between carotid artery atherosclerosis and coronary artery disease in young females. Reference to sex hormone profile. Kardiol Pol 2008, 66:127-132. discussion 33-4.
108. Orbach H., Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev 2007, 6:537-542.